Is the use of unfractionated heparin in acute coronary syndrome outmoded?

被引：0

作者：

Chiquette E. ^{[1
]}

Chilton R. ^{[1
]}

机构：

[1] Department of Medicine, Audie Murphy VA Hospital, Univ. of Texas Health Science Center, San Atonio, TX 78282

来源：

Current Atherosclerosis Reports | 2004年 / 6卷 / 2期

关键词：

Percutaneous Coronary Intervention; Acute Coronary Syndrome; Enoxaparin; Abciximab; Unfractionated Heparin;

D O I：

10.1007/s11883-004-0096-4

中图分类号：

学科分类号：

摘要：

Because of the key role of thrombin in the pathogenesis of acute coronary syndrome (ACS), the appropriate selection of antithrombotic therapy is important. Unfractionated herapin (UFH) has been the agent of choice for decades. Unfortunately, UFH has a number of limitations related to its pharmacokinetic and pharmacodynamic properties. Low molecular weight herapins (LMWHs) are attractive alternatives to UFH for several reasons, including predictable anticoagulation and ease of administration. Two LMWhs (dalteparin and enoxaparin) have been approved as alternatives to UFH in patients presenting with unstable angina and non-ST-segment elevation myocardial infarction. Randomized, controlled trials, in addition to open-label series, indicate that LMWH can safety be the agent of choice with or without glycoprotein llb/llla in the medical and upstream management of patients with ACS. Although the data are not definitive, several trials suggest that given intravenously, enoxaparin is safe as the sole antithrombotic agent in the catheterization laboratory. Copyright © 2004 by Current Science Inc.

引用

页码：94 / 100

页数：6

共 34 条

[21]

Collet J.P., Montalescot G., Lison L., Et al., Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris, Circulation, 103, pp. 658-663, (2001)

[22]

Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC-II prospective randomised multicenter study, Lancet, 354, (1999)

[23]

Fox K.A., Antman E.M., Cohen M., Et al., Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention, Am. J. Cardiol., 90, pp. 477-482, (2002)

[24]

Fox K.A., Poole-Wilson P.A., Henderson R.A., Et al., Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomised trial, Lancet, 360, pp. 743-751, (2002)

[25]

Kereiakes D.J., Kleiman N.S., Fry E., Et al., Dalteparin in combination with abciximab during percutaneous coronary intervention, Am. Heart J., 141, pp. 348-352, (2001)

[26]

Kereiakes D.J., Grines C., Fry E., Et al., Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary interventions, J. Invasive Cardiol., 4, pp. 272-278, (2001)

[27]

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade, Lancet, 352, pp. 87-92, (1998)

[28]

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization, N. Engl. J. Med., 336, pp. 1689-1696, (1997)

[29]

Bhatt D.L., Lincoff A.M., Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: The result of the CRUISE trial, Circulation, 104, pp. 384-385, (2001)

[30]

Choussat R., Montalescot G., Collet J.P., Et al., A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention, J. Am. Coll. Cardiol., 40, pp. 1943-1950, (2002)

← 1 2 3 4 →